US government challenges jury decision in Gilead HIV patent trial
The US government has asked a Delaware federal court to reverse a recent jury decision favoring Gilead in the parties’ long-running HIV drug patent battle.
The case traces back to a complaint filed in 2019 alleging Gilead’s growing HIV pre-exposure prophylaxis (PrEP) franchise benefited from the CDC’s “groundbreaking PrEP work” funded by “hundreds of millions of taxpayer dollars.” The pharma giant’s Truvada and Descovy were initially approved for the treatment of HIV in 2004 and 2016, respectively, but each won approvals years later in the preventive setting.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
